<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2631-2581</journal-id>
<journal-title><![CDATA[Revista Ecuatoriana de Neurología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Ecuat Neurol]]></abbrev-journal-title>
<issn>2631-2581</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Médica Ecuatoriana de Neurología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2631-25812021000100046</article-id>
<article-id pub-id-type="doi">10.46997/revecuatneurol30100046</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Magnetic resonance poor prognostic factors in mexican Multiple Sclerosis patients]]></article-title>
<article-title xml:lang="es"><![CDATA[Factores de mal pronóstico por resonancia magnética en pacientes mexicanos con Esclerosis Múltiple]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Bermúdez]]></surname>
<given-names><![CDATA[Ricardo Jorge]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bertado-Cortés]]></surname>
<given-names><![CDATA[Brenda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carrera-Pineda]]></surname>
<given-names><![CDATA[Raúl]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Specialities Hospital of &#8220;Siglo XXI&#8221; National Medical Center Department of Neurology ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>07</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>07</month>
<year>2021</year>
</pub-date>
<volume>30</volume>
<numero>1</numero>
<fpage>46</fpage>
<lpage>49</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.senescyt.gob.ec/scielo.php?script=sci_arttext&amp;pid=S2631-25812021000100046&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.senescyt.gob.ec/scielo.php?script=sci_abstract&amp;pid=S2631-25812021000100046&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.senescyt.gob.ec/scielo.php?script=sci_pdf&amp;pid=S2631-25812021000100046&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Multiple sclerosis is one of the main causes of disability in young people. It has characteristic lesions in magnetic resonance images which are part of diagnosis criteria, and some of them could predict a long-term disability. In mexican population there is no description about multiple sclerosis imaging characteristics.  Materials and methods:  We performed an observational, descriptive, cross-sectional, and retrolective study at the Neurology Service of Specialties Hospital of Siglo XXI National Medical Center of Mexican Social Security Institute, in Mexico, evaluating magnetic resonance images characteristics of patients with multiple sclerosis diagnosis between January 2017 and January 2020.  Results:  75 patients were included, 8% had 1-3 T2-weighted lesions, 18.6% had 4-9 T2-weighted lesions, and 73.3% had 10 or more T2-weighted lesions. 50.6% had infratentorial lesions and 61.3% had spinal cord lesions. Gadolinium enhancing lesions were found in 48%, with a median of lesions 2 (IQR 1,3).  Conclusions:  Mexican patients with multiple sclerosis have a great incidence of magnetic resonance image poor prognosis factors, which should lead to a closer follow-up and influence treatment options.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  La esclerosis múltiple es una de las principales causas de discapacidad en personas jóvenes. Se caracteriza por lesiones en resonancia magnética que forman parte de sus criterios diagnósticos, prediciendo algunas de ellas discapacidad a largo plazo. En la población mexicana no existe descripción de las características por imagen de esclerosis múltiple.  Materiales y métodos:  Desarrollamos un estudio observacional, descriptivo, retrolectivo de cohorte en el servicio de Neurología del Hospital de Especialidades del Centro Médico Nacional &#8220;Siglo XXI&#8221; del Instituto Mexicano del Seguro Social, en México, evaluando las características por imagen de resonancia magnética en pacientes con diagnóstico de esclerosis múltiple entre enero de 2017 y enero de 2020.  Resultados:  75 pacientes fueron incluidos. En secuencia T2 el 8% tuvo 1-3 lesiones, 18.6% tuvo 4-9 lesiones en secuencia T2 y 73.3% tuvo 10 o más lesiones. El 50.6% tuvieron lesiones infratentoriales y el 61.3% tuvo lesiones en médula espinal. Lesiones captantes de gadolinio se encontraron en el 48%, con una mediana de lesiones de 2 (RIC 1,3).  Conclusiones:  Los pacientes mexicanos con esclerosis múltiple tienen una gran incidencia de factores de mal pronóstico por resonancia magnética, lo cual debería de guiar a un seguimiento más estrecho e influenciar en las opciones de tratamiento.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Multiple sclerosis]]></kwd>
<kwd lng="en"><![CDATA[Mexican patients]]></kwd>
<kwd lng="en"><![CDATA[Epidemiology]]></kwd>
<kwd lng="en"><![CDATA[Prognosis]]></kwd>
<kwd lng="en"><![CDATA[Magnetic resonance]]></kwd>
<kwd lng="en"><![CDATA[Disability.]]></kwd>
<kwd lng="es"><![CDATA[Esclerosis Múltiple]]></kwd>
<kwd lng="es"><![CDATA[pacientes mexicanos]]></kwd>
<kwd lng="es"><![CDATA[epidemiología]]></kwd>
<kwd lng="es"><![CDATA[pronóstico]]></kwd>
<kwd lng="es"><![CDATA[discapacidad]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016]]></article-title>
<collab>GBD 2016 Multiple Sclerosis Collaborators</collab>
<source><![CDATA[Lancet Neurol]]></source>
<year>2019</year>
<volume>18</volume>
<page-range>269-85</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Immunopathology of multiple sclerosis.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dendrou]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fugger]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Friese]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Nature Reviews Immunology]]></source>
<year>2015</year>
<volume>15</volume>
<page-range>545-58</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevalence of multiple sclerosis in Latin America and its relationship with European migration]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Correa]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Paredes]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Multiple Sclerosis Journal Experimental, Translational and Clinical]]></source>
<year>2016</year>
<volume>2</volume>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Esclerosis múltiple en México: un estudio multicéntrico]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velázquez-Quintana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Macías-Islas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera-Olmos]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[REV NEUROL]]></source>
<year>2003</year>
<volume>36</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1019-22</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Banwell]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Barkhof]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet Neurol]]></source>
<year>2018</year>
<volume>17</volume>
<page-range>162-73</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Filippi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rocca]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ciccarelli]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet Neurol]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rotstein]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Montalban]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
</person-group>
<source><![CDATA[Nat Rev Neurol]]></source>
<year>2019</year>
<volume>15</volume>
<page-range>287-300</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fisniku]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Brex]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Altmann]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Brain]]></source>
<year>2008</year>
<volume>131</volume>
<page-range>808-17</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Early MRI in optic neuritis: the risk for disability]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Swanton]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fernando]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dalton]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurology]]></source>
<year>2009</year>
<volume>72</volume>
<page-range>542-50</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Minneboo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barkhof]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Polman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Neurol]]></source>
<year>2004</year>
<volume>61</volume>
<page-range>217-21</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brownlee]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Altmann]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Alves]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Swanton]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Multiple Sclerosis Journal]]></source>
<year>2017</year>
<volume>23</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>665-74</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Características clínicas y demográficas de los pacientes con esclerosis múltiple]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bertado-Cortés]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Villamil-Osorio]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Carrera-Pineda]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Med Inst Mex Seguro Soc]]></source>
<year>2016</year>
<volume>54</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>186-90</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Epidemiology of multiple sclerosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leray]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Moreau]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Fromont]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Revue Neurologique]]></source>
<year>2016</year>
<volume>172</volume>
<page-range>3-13</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Age and disability accumulation in multiple sclerosis.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scalfari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Neuhaus]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Daumer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurology]]></source>
<year>2011</year>
<volume>77</volume>
<page-range>1246-52</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Is time to reach EDSS 6.0 faster in patients with late-onset versus young-onset multiple sclerosis?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alroughani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Akhtar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Plos One]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Smoking and worsening disability in multiple sclerosis: A meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heydarpour]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Manouchehrinia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Beiki]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Acta Neurol Scand]]></source>
<year>2018</year>
<volume>00</volume>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comorbidity increases the risk of relapse in multiple sclerosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kowalec]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[McKay]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Patten]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurology]]></source>
<year>2017</year>
<volume>89</volume>
<page-range>2455-61</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of comorbidities on the course of multiple sclerosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Puz]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lasek-Bal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Steposz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Clinical Neurology and Neurosurgery]]></source>
<year>2018</year>
<volume>167</volume>
<page-range>76-81</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial]]></article-title>
<collab>CHAMPS study group</collab>
<source><![CDATA[Multiple Sclerosis]]></source>
<year>2002</year>
<volume>8</volume>
<page-range>330-8</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin America population]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silveira]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Pappolla]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Multiple Sclerosis and Related Disorders]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Characteristics and predictors of progression in an Egyptian multiple sclerosis cohort: a multicenter registry study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamdy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Abdel-Naseer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shalaby]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Neuropsychiatric Disease and Treatment]]></source>
<year>2017</year>
<volume>13</volume>
<page-range>1895-903</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Brain atrophy and lesion load predict long term disability in multiple sclerosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Popescu]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Agosta]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hulst]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>2013</year>
<volume>84</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1082-91</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
